Press Releases

2020.08.31 Corporate PDF (160KB)
Daiichi Sankyo Selected for AMED’s “Development of a Vaccine for COVID-19 Vaccines (Second Round)”
2020.08.31 R&D PDF (214KB)
Daiichi Sankyo Announces Results of Phase 3 Clinical Trial for Anticoagulant Edoxaban (ELDERCARE-AF Study)
2020.08.07 Corporate PDF (160KB)
Daiichi Sankyo Selected as Provider for Japanese Government’s “Emergent Initiative to Build Production Capacity for COVID-19 Vaccines (First Round)”
2020.08.07 Corporate PDF (143KB)
Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
2020.07.27 Corporate PDF (269KB)
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
2020.07.22 Corporate PDF (178KB)
Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan
2020.07.21 R&D PDF (153KB)
Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients
2020.07.10 Corporate PDF (155KB)
Daiichi Sankyo Announces Participation in AMR Action Fund
2020.07.07 R&D PDF (151KB)
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer
2020.07.02 R&D PDF (166KB)
Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer
2020.06.29 R&D PDF (166KB)
Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT
2020.06.26 Corporate PDF (158KB)
Daiichi Sankyo Announces Start of Discussions with AstraZeneca Regarding Supply in Japan of Novel Corona Virus Vaccine
2020.06.12 R&D PDF (159KB)
Daiichi Sankyo Announces Decision to Develop Vaccine in Japan for Novel Corona Virus Infection (COVID-19)
2020.06.08 Corporate PDF (142KB)
The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19)
2020.06.01 R&D PDF (309KB)
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
2020.06.01 R&D PDF (288KB)
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
2020.06.01 R&D PDF (319KB)
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial
2020.06.01 Corporate PDF (190KB)
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
2020.05.25 Products PDF (231KB)
Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
2020.05.22 R&D PDF (188KB)
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute
2020.05.22 R&D PDF (186KB)
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
2020.05.18 R&D PDF (184KB)
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
2020.05.11 R&D PDF (195KB)
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer
2020.05.11 Corporate PDF (198KB)
Daiichi Sankyo Announces Changes to Representative Directors and Members of the Board
2020.05.07 R&D PDF (252KB)
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
2020.04.27 Corporate PDF (179KB)
Daiichi Sankyo Announces Removal of Contaminated Soil Storage Facility from Site of Former Yasugawa Plant in Japan
2020.04.27 Corporate PDF (203KB)
Daiichi Sankyo Announces Share Split, Partial Amendment to the Articles of Incorporation, and Forecast of Annual Dividend per Share for the Year Ending March 31, 2021
2020.04.14 CSR PDF (160KB)
Daiichi Sankyo Contributes to Relief Efforts for Countermeasures against COVID-19
2020.04.13 R&D PDF (175KB)
Daiichi Sankyo, Mitsubishi UFJ Capital and Nagoya Institute of Technology Announce Open Innovation Research on Gene Therapy to Restore Vision
2020.04.01 Corporate PDF (161KB)
Daiichi Sankyo Enters into Strategic Partnership with Ultragenyx for Use of Gene Therapy Manufacturing Technology
2020.03.30 R&D PDF (174KB)
Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan
2020.03.27 Corporate PDF (149KB)
Daiichi Sankyo and Kitasato Pharmaceutical Industry to End Sales Cooperation for Influenza HA Vaccine “Daiichi Sankyo” in Japan
2020.03.25 Products PDF (271KB)
ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
2020.02.27 R&D PDF (111KB)
Anti-epilepsy Drug VIMPAT ®, Submission for Supplemental Application for Approval in Japan
2020.02.21 Corporate PDF (119KB)
Daiichi Sankyo Appoints New Corporate Officers
2020.01.27 R&D PDF (77KB)
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
2020.01.07 Products PDF (244KB)
ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens

In order to view the PDF files, you need to have the latest version of Adobe Reader installed.